Weiss K, Laverdiere M, Restieri C
Department of Infectious Diseases and Microbiology, Hôpital Maisonneuve-Rosemont, University of Montreal, Québec, Canada.
J Antimicrob Chemother. 1998 Oct;42(4):523-5. doi: 10.1093/jac/42.4.523.
The principal aim of this study was to evaluate the in-vitro activity of new quinolones against clinical strains of Streptococcus pneumoniae. Four hundred and fifty-two single clinical isolates (of which 362 were susceptible to penicillin, 54 intermediate and 36 highly resistant) were tested against penicillin, cefuroxime, ciprofloxacin, levofloxacin, trovafloxacin and Bay 12-8039. Of the tested S. pneumoniae strains, 97.1 % had MICs of trovafloxacin of < or = 0.25 mg/L, and 96.7% had MICs of Bay 12-8039 of < or = 0.25 mg/L (difference not statistically significant); 81.9% of strains had MICs of cefuroxime of < or = 0.25 mg/L (P < or = 0.001 against both quinolones). Only 4% and 0.7% of the strains had MICs of levofloxacin and ciprofloxacin respectively of < or = 0.25 mg/L. Compared with older quinolones, trovafloxacin and Bay 12-8039 have good in-vitro activity against S. pneumoniae.
本研究的主要目的是评估新型喹诺酮类药物对肺炎链球菌临床菌株的体外活性。对452株单一临床分离株（其中362株对青霉素敏感，54株中介，36株高度耐药）进行了针对青霉素、头孢呋辛、环丙沙星、左氧氟沙星、曲伐沙星和Bay 12 - 8039的测试。在受试的肺炎链球菌菌株中，97.1%的曲伐沙星MICs≤0.25mg/L，96.7%的Bay 12 - 8039 MICs≤0.25mg/L（差异无统计学意义）；81.9%的菌株头孢呋辛MICs≤0.25mg/L（与两种喹诺酮类药物相比P≤0.001）。只有4%和0.7%的菌株左氧氟沙星和环丙沙星MICs分别≤0.25mg/L。与 older quinolones相比，曲伐沙星和Bay 12 - 8039对肺炎链球菌具有良好的体外活性。 （注：原文中“older quinolones”表述不太准确，推测可能是“老一代喹诺酮类药物”，但按照要求未做修改）
